RESUMEN
North American researchers' perspectives on designing neurosurgical implant studies for Parkinson disease (PD) challenged the custom of holding surgical trials to less stringent evidentiary standards than other clinical studies. Researchers supported placebo surgery-controlled trials. The framework they used to design and evaluate studies both of deep brain stimulation and cellular implants for PD may be applicable to a broad range of surgical implants for other disorders.
Asunto(s)
Investigación Biomédica , Trasplante de Células , Estimulación Encefálica Profunda , Enfermedad de Parkinson/terapia , Proyectos de Investigación/normas , HumanosRESUMEN
Reasoned and defensible coverage decisions are essential for a fairer and more efficient healthcare system. Because healthcare resources are finite, coverage decisions should be informed by economic evaluations and made from a perspective that attends to the interests of both individuals and the population enrolled in a plan as a whole. Coverage decisions for all healthcare interventions should follow a 2-step procedure that consists of (1) the relatively impartial and objective assessment of an intervention's eligibility for coverage and (2) the distinctively value-laden determination (for which the enrolled population's values and preferences should take priority) to cover, conditionally cover, or not cover an intervention.
Asunto(s)
Toma de Decisiones , Determinación de la Elegibilidad/métodos , Asignación de Recursos para la Atención de Salud/economía , Cobertura del Seguro , Eficiencia Organizacional , Determinación de la Elegibilidad/clasificación , Humanos , Modelos Organizacionales , Política Organizacional , Trabajo de Rescate/economía , Justicia Social , Estados UnidosAsunto(s)
Grupos Control , Ética Médica , Trasplante de Tejido Fetal , Enfermedad de Parkinson/cirugía , Placebos , Ensayos Clínicos Controlados Aleatorios como Asunto , Medición de Riesgo , Sustancia Negra/trasplante , Experimentación Humana Terapéutica , Adulto , Comités Consultivos , Revelación , Método Doble Ciego , Revisión Ética , Comités de Ética en Investigación , Gobierno Federal , Humanos , Efecto Placebo , Ensayos Clínicos Controlados Aleatorios como Asunto/normas , Proyectos de Investigación , Sujetos de Investigación , Sustancia Negra/embriologíaAsunto(s)
Asiático , Actitud del Personal de Salud , Beneficencia , Comparación Transcultural , Diversidad Cultural , Ética Médica , Paternalismo , Autonomía Personal , Negativa del Paciente al Tratamiento/legislación & jurisprudencia , Adulto , Hijos Adultos , Anciano , Quistes/complicaciones , Quistes/terapia , Disentimientos y Disputas , Familia , Femenino , Procesos de Grupo , Humanos , Consentimiento Informado/legislación & jurisprudencia , Intubación Intratraqueal , Masculino , Grupo de Atención al Paciente/legislación & jurisprudencia , Valores Sociales , Enfermedades de la Tiroides/complicaciones , Enfermedades de la Tiroides/terapia , Estenosis Traqueal/etiología , Estenosis Traqueal/terapia , Confianza , Privación de TratamientoRESUMEN
A review of human fetal tissue policies over the past 40 years reveals an increasing awareness that the use of this tissue raises unique ethical and policy issues. Initially it was believed that the use of fetal tissue was no different from using any other abandoned surgical waste specimen. Then state laws were passed requiring fetal tissue to be treated with the same respect and protection as tissue obtained from cadaver donors generally. Most recently, a few state and federal policies suggest that the use of fetal tissue requires a unique set of provisions, that it is unlike either the use of tissue from a routine cadaver donor or the use of tissue from abandoned waste specimens. In this paper we identify four central features of fetal tissue donation that make it a unique type of tissue donation requiring its own framework of respect and protection for the parties involved. We then critically review the most important current state and federal fetal tissue policies, including the NIH Revitalization Act of 1993.
Asunto(s)
Ética Médica , Trasplante de Tejido Fetal/legislación & jurisprudencia , Política Pública , Donantes de Tejidos/legislación & jurisprudencia , Humanos , Control Social Formal , Estados UnidosAsunto(s)
Ética Médica , Rehabilitación/normas , Encefalopatías , Humanos , Asignación de Recursos , Estados UnidosRESUMEN
PIP: Researchers believe fetal tissue can be easily transplanted into and cure people with incurable debilitating diseases such as Parkinson's disease. In 1988, the Reagan Administration stopped funding transplantation research of fetal tissue from induced abortions. An advisory panel later decided that it is an acceptable public policy as long as certain conditions a re met. Yet the Bush Administration continued the ban. In 1992, it erroneously claimed that transplantation research could use alternative sources of fetal tissue. 1 alternative is fetal tissue obtained from ectopic pregnancies. Yet spontaneously aborted ectopic pregnancies tend not to produce recognizable or viable in culture fetal tissue and if they do the tissue has been ischemic for days. Ectopic pregnancies requiring surgical sterilization tend to be morphologically abnormal. The only likelihood of viable fetal tissue form ectopic pregnancies is a fetus with myocardial contractility before surgery. The administration also recommended use of fetal tissue from spontaneous abortions but these fetuses often have a major chromosomal or other fatal defect. Researchers cannot use chromosomally abnormal fetal tissue since it growth, development, and function are unreliable. Expulsion of the necrotic fetus tends to occur a couple of weeks after death. The Bush Administration also proposed use of tissue from stillbirths but their tissue tends to be nonviable and the tissue, even if it were viable, is generally not at the developmental stage needed for transplantation. The placenta and yolk sac were other suggested alternatives, but the placenta is likely to be less immunogenic than embryonic tissue. It can help develop certain cell lines which produce insulin or neurotransmitters like dopamine, however. The yolk sac could replace fetal liver cells in transplantation. Nevertheless the only advantage of using the suggested alternatives is the perception of them raising less ethical concern than fetal tissue from an induced abortion.^ieng
Asunto(s)
Aborto Espontáneo/patología , Trasplante de Tejido Fetal , Embarazo Ectópico/patología , Aborto Inducido , Ética Médica , Femenino , Muerte Fetal/patología , Feto/patología , Humanos , National Institutes of Health (U.S.) , Placenta , Embarazo , Supervivencia Tisular , Estados Unidos , Saco VitelinoRESUMEN
The bill to restore federal funding for human fetal tissue research has been passed by the House and awaits Senate approval. But it requires women who are willing to donate fetal tissue to certify that they did not have an abortion with the intent to donate. It further requires researchers to keep the certifications on file and available for government audit. Both requirements spell trouble.
PIP: H.R. 2507 passed by the US House of Representatives, is an attempt to end the ban on fetal tissue research. However it signals a new era in government violation of privacy and ultimately will undermine its own stated purpose. The law provides that any woman wishing to donate the fetal tissue from an abortion must sign 2 ethical intent forms. The 1st stating that the decision to donate was made independently of the decision to abort. The 2nd stating that the reason for aborting was not to donate fetal tissue. These forms of ethical intent are to be kept on file by the researchers using the fetal tissue and are to be made available for audit to ensure compliance. The law does not have any provision for protecting the confidentiality of these forms, nor does it state whose property they become. It also does not state who allowed to audit the records or whose responsibility it is. The results of this law are that women fearing exposure of their name in a document open to public audit will not want to donate. Further, in many states this failure to sign the forms can be legally viewed as intent to abort for donation and thus the abortion could be denied. In addition, researchers will not want to cover the expense or controversy surrounding these records and as such will refuse to accept fetal tissue.